The Japan Marrow Donor Program, 25 years of experience in achieving 20,000 bone marrow transplantations: organization structure, activity, and financial basis.

abstract：:Forty-two patients allografted for multiple myeloma after not having attained at least a partial remission (n = 19) or after having experienced disease progression (n = 23) following one autograft were compared with 42 pair-matched controls who underwent salvage autotransplantation under identical conditions. Autograf...

journal_title：Bone marrow transplantation

authors： Mehta J,Tricot G,Jagannath S,Ayers D,Singhal S,Siegel D,Desikan K,Munshi N,Fassas A,Mattox S,Vesole D,Crowley J,Barlogie B

更新日期：1998-05-01 00:00:00

abstract：:Conflicting conclusions can be drawn from the available data concerning antileukemic efficacy and risks of intrathecal (i.t.) chemoprophylaxis to children after hematopoietic SCT (HSCT). To address this, we enrolled six transplantation centers with similar treatment and patient material. Of the 397 children included, ...

journal_title：Bone marrow transplantation

authors： Rubin J,Vettenranta K,Vettenranta J,Bierings M,Abrahamsson J,Békássy AN,Håkansson Y,Frost BM,Arvidson J,Spendilow C,Winiarski J,Gustafsson B

更新日期：2011-03-01 00:00:00

abstract：:A fatal case of EBV-associated lymphoproliferative disorder arising after a CD34-selected autologous peripheral blood stem cell transplant is reported in a patient with multiple myeloma in first plateau phase. It is suggested that this is likely to be a consequence of the accessory cell depletion associated with the C...

journal_title：Bone marrow transplantation

authors： Peniket AJ,Perry AR,Williams CD,MacMillan A,Watts MJ,Isaacson PG,Goldstone AH,Linch DC

更新日期：1998-08-01 00:00:00

abstract：:The protection of hematopoietic stem and progenitor cells and their environment is required for recovery from radiation-induced (RI) myelosuppression. To achieve this goal, we propose a new gene therapy strategy based on local and short-term synthesis and expression of Sonic hedgehog morphogene (Shh) at the niche leve...

journal_title：Bone marrow transplantation

authors： Drouet M,Garrigou P,Peinnequin A,Hérodin F

更新日期：2014-02-01 00:00:00

abstract：:Reconstitution of the adaptive immune system following allogeneic hematopoietic stem cell transplantation is crucial for beneficial outcome and is affected by several factors, such as GvHD and graft source. The impact of these factors on immune reconstitution has been thoroughly investigated during the early phase aft...

journal_title：Bone marrow transplantation

authors： Gaballa A,Norberg A,Stikvoort A,Mattsson J,Sundberg B,Uzunel M,Remberger M,Uhlin M

更新日期：2018-01-01 00:00:00

abstract：:We report two cases of secondary myelodysplastic syndrome (SMDS) which followed successful treatment of a primary malignancy with high-dose chemotherapy supported by reinfusion of autologous stem cells. The SMDS was diagnosed 24 months and 40 months, respectively, following autografting. Both patients lived for 7 mont...

journal_title：Bone marrow transplantation

authors： Chan T,Juneja S,Wolf M,Januszewicz E,Cooper I

更新日期：1994-02-01 00:00:00

abstract：:Patients with primary metastatic or recurrent rhabdomyosarcoma (RMS) have a very poor prognosis. Since high-dose chemotherapy (HDC) +/- TBI was thought to improve survival, many centers performed this therapy using different types of hematopoietic rescue (auto BM or PBSC, allo BM). This is a retrospective, multi-cente...

journal_title：Bone marrow transplantation

authors： Koscielniak E,Klingebiel TH,Peters C,Hermann J,Burdach ST,Bender-Götze C,Müller-Weihrich ST,Treuner J

更新日期：1997-02-01 00:00:00

abstract：:High-dose carboplatin, etoposide and ifosfamide (CEI) is an active chemotherapy regimen (HDCT) in solid tumors and lymphomas. In patients with previous exposure to cisplatin, its nephrotoxicity is dose-limiting. To determine the implications of nephrotoxicity on hematological recovery and clinical outcome, we analyzed...

journal_title：Bone marrow transplantation

authors： Beyer J,Rick O,Weinknecht S,Kingreen D,Lenz K,Siegert W

更新日期：1997-11-01 00:00:00

abstract：:We examined whether pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) is capable of improving thrombocytopenia and promoting thrombopoietic reconstitution following lethal irradiation and bone marrow transplantation (BMT) in mice. Immediately after receiving 10 Gy whole body irradia...

journal_title：Bone marrow transplantation

authors： Kabaya K,Shibuya K,Torii Y,Nitta Y,Ida M,Akahori H,Kato T,Kusaka M,Miyazaki H

更新日期：1996-12-01 00:00:00

abstract：:Depletion of donor CD6+ cells in HLA-identical allogeneic bone marrow transplantation has been reported to reduce graft-versus-host disease without interfering with engraftment. We have established an immunomagnetic cell separation technique capable of producing a 2-3 log depletion of CD6+ cells. Median recovery of CD...

journal_title：Bone marrow transplantation

authors： Egeland T,Albrechtsen D,Martin PJ,Hansen JA

更新日期：1990-03-01 00:00:00

abstract：:Adenovirus has been recognised as an important pathogen in BMT recipients, especially in patients with GVHD and those receiving T cell-depleted allografts. We report adenovirus infections from an ongoing surveillance study in four patients after a non-myeloablative transplant and their improved outcome following withd...

journal_title：Bone marrow transplantation

authors： Chakrabarti S,Collingham KE,Fegan CD,Pillay D,Milligan DW

更新日期：2000-08-01 00:00:00

abstract：:Allogeneic hematopoietic stem cell transplantation (ASCT) and its conditioning with chemoradiotherapy often results in liver toxicity, the most severe form being veno-occlusive liver disease (VOD). N-acetyl-L-cysteine (NAC), an antioxidant glutathione precursor, may provide protection from liver toxicity. Patients wit...

journal_title：Bone marrow transplantation

authors： Barkholt L,Remberger M,Hassan Z,Fransson K,Omazic B,Svahn BM,Karlsson H,Brune M,Hassan M,Mattsson J,Ringdén O

更新日期：2008-05-01 00:00:00

abstract：:We describe the long-term outcomes of autologous hematopoietic cell transplantation (HCT) for 315 AML patients in first or second complete remission (CR). All patients were in continuous CR for ≥2 years after HCT. Patients were predominantly transplanted in CR1 (78%) and had good or intermediate cytogenetic risk disea...

journal_title：Bone marrow transplantation

authors： Majhail NS,Bajorunaite R,Lazarus HM,Wang Z,Klein JP,Zhang MJ,Rizzo JD

更新日期：2011-03-01 00:00:00

abstract：:Thirty two allogeneic bone marrow transplant (BMT) recipients, aged 16-55 (median 35), with CMV antigenemia (= > 5 positive cells) developing at a median interval from BMT of 49 days, were given combined treatment with foscarnet and ganciclovir for 15 days. Maintenance was given with foscarnet and ganciclovir on alter...

journal_title：Bone marrow transplantation

authors： Bacigalupo A,Bregante S,Tedone E,Isaza A,Van Lint MT,Moro F,Trespi G,Occhini D,Gualandi F,Lamparelli T,Marmont AM

更新日期：1996-11-01 00:00:00

abstract：:Brain injury resulting from perinatal hypoxic-ischemic encephalopathy (HIE) is a major cause of acute mortality in infants and chronic neurologic disability in surviving children. Recent multicenter clinical trials demonstrated the effectiveness of hypothermia initiated within the first 6 postnatal hours to reduce the...

journal_title：Bone marrow transplantation

authors： Liao Y,Cotten M,Tan S,Kurtzberg J,Cairo MS

更新日期：2013-07-01 00:00:00

abstract：:Between December 1979 and February 1991, 89 patients with ALL received autologous BMT. Median patient age was 18.4 years. Ten patients were in first remission, 52 were in second or greater remission and 27 were in relapse at the time of transplant. Conditioning regimens utilized chemotherapy alone (5 patients) or in c...

journal_title：Bone marrow transplantation

authors： Doney K,Buckner CD,Fisher L,Petersen FB,Sanders J,Appelbaum FR,Anasetti C,Badger C,Bensinger W,Deeg HJ

更新日期：1993-10-01 00:00:00

abstract：:In 8 homozygous beta-thalassemic patients, aged between 1.9 and 18 years, that received bone marrow transplantation (BMT), a longtidinal study of growth before and after BMT and relative Height Standard Deviation Score (SDS), has been performed. In all patients, also after BMT, a progressive growth retardation has bee...

journal_title：Bone marrow transplantation

authors： Ponte G,Ferrara M,Esposito L

更新日期：1991-01-01 00:00:00

abstract：:During this study, BalB/C mice were used as recipients and C57 bl/6 mice as donors. Recipients were given 800 cGys of total body irradiation (TBI) on day 0. Transplantation was carried out as follows: group (1): TBI on day 0; group (2): TBI on day 0 and transplantation on day +1; group (3): TBI on day 0 and transplant...

journal_title：Bone marrow transplantation

authors： Mabed M,Maroof S,Zalta K,El-Awadee M

更新日期：2005-04-01 00:00:00

abstract：:We examined the role of fluorodeoxyglucose-positron emission tomography (FDG-PET) and the addition of involved field radiotherapy (IFRT) as potential modifiers of salvage therapy. From January 2000 to June 2007, 83 patients with chemosensitive relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) underw...

journal_title：Bone marrow transplantation

authors： Hoppe BS,Moskowitz CH,Zhang Z,Maragulia JC,Rice RD,Reiner AS,Hamlin PA,Zelenetz AD,Yahalom J

更新日期：2009-06-01 00:00:00

abstract：:A 41-year-old male with IgG kappa multiple myeloma is described. He developed a free gamma heavy chain without an accompanying light chain following high-dose chemotherapy and autologous peripheral blood stem cell transplantation. The free gamma heavy chain was detected in serum and urine specimens 2 months after tran...

journal_title：Bone marrow transplantation

authors： Butch AW,Badros A,Desikan KR,Munshi NC

更新日期：2001-03-01 00:00:00

abstract：:Since approximately 30% of leukemia patients relapse after allogeneic BMT using total body irradiation (TBI)-based preparative regimens, treatment intensity may be suboptimal. The killing of leukemia cells is proportional to the radiation absorbed dose. We studied the feasibility and toxicity of escalating the doses o...

journal_title：Bone marrow transplantation

authors： Sobecks RM,Daugherty CK,Hallahan DE,Laport GF,Wagner ND,Larson RA

更新日期：2000-04-01 00:00:00

abstract：:In patients with acute myeloid leukemia (AML) consolidation treatment options are between allogeneic hematopoietic stem cell transplantation (HCT) and chemotherapy, based on disease risk at the time of initial presentation and age. Measurable residual disease (MRD) following induction chemotherapy could be incorporate...

journal_title：Bone marrow transplantation

authors： Ahn JS,Kim T,Jung SH,Ahn SY,Jung SY,Song GY,Kim M,Yang DH,Lee JJ,Choi S,Lee JY,Park SK,Moon JH,Lee HY,Kim KH,Cai Y,Yi SY,Novitzky-Basso I,Zhang Z,Kim HJ,Kim DDH

更新日期：2020-12-05 00:00:00

abstract：:Fetus-to-fetus transplantation has been suggested for the treatment of hemoglobinopathies in utero. However, dissimilar results have to date been obtained by different groups. We describe a case in which fetus-to-fetus transplantation in HLA-identical twins was performed at the 19th week of gestation by infusion of 0....

journal_title：Bone marrow transplantation

authors： Orlandi F,Giambona A,Messana F,Marino M,Abate I,Calzolari R,Damiani F,Jakil C,Renda M,Dieli F,Buscemi F,Westgren M,Ringden O,Maggio A

更新日期：1996-09-01 00:00:00

abstract：:We have undertaken a formal study to evaluate the reproducibility of retrospective assessments for grading the severity of acute GVHD. Using criteria previously established by the Seattle group, three reviewers independently assigned GVHD severity grades for a set of 100 marrow transplant patients. Significant differe...

journal_title：Bone marrow transplantation

authors： Martin P,Nash R,Sanders J,Leisenring W,Anasetti C,Deeg HJ,Storb R,Appelbaum F

更新日期：1998-02-01 00:00:00

abstract：:Between July 1990 and March 2002, 35 consecutive children with ALL in third complete remission (CR3) underwent stem cell transplantation (SCT) from unrelated donors (UD). All patients received CAMPATH-1M 5-20 mg daily for 5 days. Grafts were T-cell depleted in 30 patients, 29 by CAMPATH antibodies and one by CD34 sele...

journal_title：Bone marrow transplantation

authors： Afify Z,Hunt L,Green A,Guttridge M,Cornish J,Oakhill A

更新日期：2005-06-01 00:00:00

abstract：:Among the drugs used in conditioning regimens for stem cell transplantation, high-dose melphalan (HDM) plays an important role for both its strong myeloablative effect and for its favourable dose-response ratio. Here we report five cases of high frequency atrial fibrillation (AF) developing after HDM. Duration of the ...

journal_title：Bone marrow transplantation

authors： Olivieri A,Corvatta L,Montanari M,Brunori M,Offidani M,Ferretti GF,Centanni M,Leoni P

更新日期：1998-05-01 00:00:00

abstract：:The incidence of varicella-zoster-virus infection/reactivation in adult patients with Hodgkin's disease undergoing autologous bone marrow transplantation (BMT) at the University of Minnesota Hospital and Clinic was determined. Seven of 28 evaluable patients (25%) developed varicella-zoster infections in the first 150 ...

journal_title：Bone marrow transplantation

authors： Christiansen NP,Haake RJ,Hurd DD

更新日期：1991-06-01 00:00:00

abstract：:We evaluated 120 leukapheresis procedures (93 patients), in order to detect clinical factors that influence the efficiency of CD34+ collection using Cobe Spectra trade mark cell separators. Hematocrit was >27% and platelet count >30 000/microl in >95% of patients. Platelet transfusions were given if the postprocedure ...

journal_title：Bone marrow transplantation

authors： Sarkodee-Adoo C,Taran I,Guo C,Buadi F,Murthy R,Cox E,Lopez R,Westphal S,Shope S,O'Connell B,Wethers L,Meisenberg B

更新日期：2003-05-01 00:00:00

abstract：:Allogeneic SCT for older patients remains challenging at least in part due to graft-versus-host disease (GVHD) and higher non-relapse mortality (NRM). We conducted a prospective pilot study primarily for older patients undergoing matched unrelated donor (MUD) SCT using a reduced-intensity (RIC) melphalan-based conditi...

journal_title：Bone marrow transplantation

authors： Shah MV,Saliba RM,Rondon G,Chen J,Soebbing D,Rus I,Alousi A,Oran B,Kebriaei P,Qazilbash M,Parmar S,Hosing C,Khouri IF,Popat UR,Champlin RE,Ciurea SO

更新日期：2019-04-01 00:00:00

abstract：:A 38-year-old woman with agnogenic myeloid metaplasia complicated by the poor prognostic factors of severe osteosclerosis, prominent hepatosplenomegaly, and profound anemia was treated with FLAG chemotherapy to decrease her organomegaly before undergoing a nonmyeloablative allogeneic stem cell transplant from a matche...

journal_title：Bone marrow transplantation

authors： Tanner ML,Hoh CK,Bashey A,Holman P,Sun C,Broome HE,Lane T,Ball ED,Carrier E

更新日期：2003-09-01 00:00:00